GLP-1 Lawsuit Timeline — Active Case Updates 2026

Cases involving gastroparesis and NAION are actively being consolidated into Multi-District Litigation in federal court. Law firms across the country are building case inventories now. Over 3,000 cases have been filed or are in pre-filing stages as of this update. This is the period of highest activity — qualified plaintiffs who come forward now position themselves best for early resolution.

The FDA issued formal warning letters to multiple GLP-1 telehealth platform operators regarding misleading labeling and safety claims. This regulatory action strengthened the legal basis for patient lawsuits by confirming the FDA's concern about how these medications were being marketed and monitored.

Personal injury firms began formally organizing GLP-1 mass tort dockets. National advertising campaigns for injured patients began. Law firms reported receiving thousands of inquiries from patients who experienced gastroparesis, vision loss, and pancreatitis after GLP-1 use.

Harvard Medical School researchers published a peer-reviewed study finding a statistically significant elevated risk of NAION — sudden vision loss — among semaglutide users. This study became the cornerstone of vision-loss lawsuits and received widespread coverage in both medical and mainstream press.

Early plaintiffs filed individual lawsuits citing severe gastroparesis, intestinal obstruction, and stomach paralysis after Ozempic and Wegovy use. These cases established the legal arguments now being applied across thousands of similar claims in mass tort proceedings.

The FDA required GLP-1 manufacturers to add black box warnings regarding the risk of thyroid tumors and pancreatitis. Lawsuits now allege these warnings were insufficient and patients were not adequately counseled by prescribers who were not fully informed themselves.